Glucovis Ophthalmic Solution 0.25%
Glucovis Ophthalmic Solution 0.25% Uses, Dosage, Side Effects, Food Interaction and all others data.
| Trade Name | Glucovis Ophthalmic Solution 0.25% |
| Generic | Betaxolol Hydrochloride |
| Weight | 0.25% |
| Type | Ophthalmic Solution |
| Therapeutic Class | Drugs for miotics and glaucoma |
| Manufacturer | Beximco Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Betaxolol ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. May be used alone or in combination with other intraocular pressure-lowering medication.Dosage
Glucovis Ophthalmic Solution 0.25% dosage
0.5% ophthalmic solution: The usual dose is 1 drop of Glucovis Ophthalmic Solution 0.25% ophthalmic solution in the affected eye(s) twice daily. In some patients, the intraocular pressure-lowering response may require a few weeks to stabilize. Clinical follow-up should include a determination of the intraocular pressure during the first month of treatment. Thereafter, intraocular pressure should be determined on an individual basis at the judgment of the physician.0.25% ophthalmic solution: The recommended dose is one to two drops of Glucovis Ophthalmic Solution 0.25% ophthalmic solution in the affected eye(s) twice daily.Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: No overall differences in safety or effectiveness have been observed between elderly and younger patients.Side Effects
Ocular: Discomfort of short duration, occasional tearing has been reported. Rare instances of decreased corneal sensitivity, erythema, itching sensation, corneal punctuate staining, keratitis, edema and photophobia have been reported.Systemic: Systemic reactions following administration of Betaxolol hydrochloride ophthalmic solution 0.5% have been rarely reported. These include: Cardiovascular: bradycardia, heart block, congestive heart failure. Respiratory: bronchospasm, respiratory failure. Others: Hives, toxic epidermal necrolysis, hair loss and glossitis.Precaution
In patients with angle-closure glaucoma, the immediate treatment objective is to re-open the angle by constriction of the pupil with miotic agent. Betaxolol has no effect on the pupil; therefore, Betaxolol should be used with a miotic to reduce elevated intraocular pressure in angle-closure glaucoma. Beta-adrenergic blocking agents should be administered with caution in patients subjected to spontaneous hypoglycemia or to diabetic patients as these agents may mask the signs and symptoms of acute hypoglycemia.Interaction
Patients who are receiving a beta-adrenergic blocking agent orally and Glucovis Ophthalmic Solution 0.25% Ophthalmic Solution should be observed for a potential additive effect either on the intraocular pressure or on the known systemic effects of beta blockade. Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or bradycardia. Caution should be exercised in patients using concomitant adrenergic psychotropic drugs. In patients with angle-closure glaucoma, the immediate treatment objective is to reopen the angle by constriction of the pupil with a miotic agent. Betaxolol has little or no effect on the pupil. When Glucovis Ophthalmic Solution 0.25% Ophthalmic Solution is used to reduce elevated intraocular pressure in angle-closure glaucoma, it should be used with a miotic and not alone.Pregnancy & Breastfeeding use
There are no adequate & well controlled studies in pregnant women. Betaxolol ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk. It is not known whether Betaxolol is excreted in human milk. The risk of hypoglycemia & bradycardia in nursing infant has not been evaluated. Breast feeding is not recommended during treatment.Contraindication
Hypersensitivity to any component of this product. Betaxolol should not be used in patients with sinus bradycardia, atrioventricular block greater than first degree, cardiogenic shock, or patients with a history of overt cardiac failure.Acute Overdose
No information is available on overdosage. A topical overdosage of Betaxolol ophthalmic solution may be flushed from the eye(s) with warm tap water.Storage Condition
Store at room temperature. It is desirable that the content should not be used more than one month after first opening of the bottle.Innovators Monograph
You find simplified version here Glucovis Ophthalmic Solution 0.25%
